Reed Smith’s Life Sciences Health Industry Group is hosting a Life Sciences CLE Day at our Philadelphia office on Thursday, November 10. The day starts with breakfast and networking at 8:30 a.m. and sessions commence at 9 a.m. The event, which includes a working lunch, concludes at 2:30 p.m. This program is geared toward in-house counsel; space is limited.
Sessions include:
- “Major Drug and Device Decisions of 2016” presented by Eric Alexander and Kelly Hibbert
- “FCA Post-Escobar: Materiality Matters” presented by Thomas Suddath, Brian Himmel, and Lindsey Harteis
- “Purple is the New Orange: A Primer on the Biologics-Biosimilars Landscape,” presented by Lisa Chiarini and Rudolf Hutz
- “Looking for Law in All the Wrong Places: Perspectives on the Best (and Worst) Product Liability Jurisdictions,” presented by Rick Fuentes Ph.D., Barbara Binis, Melissa Geist, and Marilyn Moberg
- “Regulating Healthcare on a New Wavelength: The FCC’s Role In Wireless Medical Devices,” presented by Paul Bond and Samuel Cullari
- “Implied Preemption – It’s Not Just for Generic Drugs Anymore (Plus Off-Label Promotions Update),” presented by James Beck and Rachel Weil
The CLE Day is presumptively approved for 6 CLE credits in New Jersey and 5 CLE credits in Pennsylvania. An application for Delaware credit is pending. For lawyers licensed in New York, this course is eligible for 6 credits under New York’s Approved Jurisdiction Policy. We hope to see you there!
For more information, or to register, please visit our website.
